Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint.
Cell cycle checkpoints are implemented to safeguard the genome, avoiding the accumulation of genetic errors. Checkpoint loss results in genomic instability and contributes to the evolution of cancer. Among G1-, S-, G2- and M-phase checkpoints, genetic studies indicate the role of an intact S-phase checkpoint in maintaining genome integrity. Although the basic framework of the S-phase checkpoint in multicellular organisms has been outlined, the mechanistic details remain to be elucidated. Human chromosome-11 band-q23 translocations disrupting the MLL gene lead to poor prognostic leukaemias. Here we assign MLL as a novel effector in the mammalian S-phase checkpoint network and identify checkpoint dysfunction as an underlying mechanism of MLL leukaemias. MLL is phosphorylated at serine 516 by ATR in response to genotoxic stress in the S phase, which disrupts its interaction with, and hence its degradation by, the SCF(Skp2) E3 ligase, leading to its accumulation. Stabilized MLL protein accumulates on chromatin, methylates histone H3 lysine 4 at late replication origins and inhibits the loading of CDC45 to delay DNA replication. Cells deficient in MLL showed radioresistant DNA synthesis and chromatid-type genomic abnormalities, indicative of S-phase checkpoint dysfunction. Reconstitution of Mll(-/-) (Mll also known as Mll1) mouse embryonic fibroblasts with wild-type but not S516A or ΔSET mutant MLL rescues the S-phase checkpoint defects. Moreover, murine myeloid progenitor cells carrying an Mll-CBP knock-in allele that mimics human t(11;16) leukaemia show a severe radioresistant DNA synthesis phenotype. MLL fusions function as dominant negative mutants that abrogate the ATR-mediated phosphorylation/stabilization of wild-type MLL on damage to DNA, and thus compromise the S-phase checkpoint. Together, our results identify MLL as a key constituent of the mammalian DNA damage response pathway and show that deregulation of the S-phase checkpoint incurred by MLL translocations probably contributes to the pathogenesis of human MLL leukaemias.
Liu
Han
H
Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA.
Takeda
Shugaku
S
Kumar
Rakesh
R
Westergard
Todd D
TD
Brown
Eric J
EJ
Pandita
Tej K
TK
Cheng
Emily H-Y
EH
Hsieh
James J-D
JJ
D000483:Alleles; D000818:Animals; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins / Q000378:metabolism*; D002460:Cell Line; D002843:Chromatin / Q000378:metabolism; D004249:DNA Damage; D004261:DNA Replication / Q000502:physiology; D005799:Genes, Dominant / Q000235:genetics; D042822:Genomic Instability / Q000502:physiology; D011495:Histone-Lysine N-Methyltransferase; D006657:Histones / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000235:genetics; D008239:Lysine / Q000378:metabolism; D008745:Methylation; D051379:Mice; D023461:Myeloid Progenitor Cells / Q000378:metabolism; D051788:Myeloid-Lymphoid Leukemia Protein / Q000737:chemistry / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D010768:Phosphoserine / Q000378:metabolism; D011485:Protein Binding; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D016196:S Phase / Q000502:physiology*; D044786:S-Phase Kinase-Associated Proteins / Q000378:metabolism; D015398:Signal Transduction; D014178:Translocation, Genetic / Q000235:genetics
C113571:CDC45 protein, human; D018797:Cell Cycle Proteins; D002843:Chromatin; D006657:Histones; C497422:KMT2A protein, human; D044786:S-Phase Kinase-Associated Proteins; D051788:Myeloid-Lymphoid Leukemia Protein; D010768:Phosphoserine; D011495:Histone-Lysine N-Methyltransferase; C576897:Atr protein, mouse; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases; D008239:Lysine
Immunity. 1998 Sep;9(3):355-66
9768755
Nature. 1995 Nov 30;378(6556):505-8
7477409
Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27
18594563
Nature. 2004 Nov 18;432(7015):316-23
15549093
Genes Dev. 2003 Mar 1;17(5):615-28
12629044
Genes Dev. 2007 Oct 1;21(19):2385-98
17908926
EMBO J. 2005 Jan 26;24(2):368-81
15635450
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14028-33
16169901
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10632-6
9724755
Cell Stem Cell. 2007 Sep 13;1(3):324-37
18371366
Cell. 2005 Aug 26;122(4):579-91
16122425
EMBO J. 2006 Oct 18;25(20):4795-807
17006541
Genes Chromosomes Cancer. 2006 Aug;45(8):754-60
16688745
Cancer Biol Ther. 2009 Jul;8(13):1204-11
19729989
Mol Cell Biol. 2008 Jan;28(1):397-409
17967868
Methods Enzymol. 2006;409:251-84
16793406
Nat Rev Cancer. 2007 Nov;7(11):823-33
17957188
Genes Dev. 2006 Sep 1;20(17):2397-409
16951254
Cell. 2003 Oct 31;115(3):293-303
14636557
Mol Cell. 2002 Nov;10(5):1107-17
12453418
Mol Cell. 2006 Oct 6;24(1):101-13
17018296
Nature. 1998 Oct 8;395(6702):615-8
9783589
Nat Cell Biol. 2006 Dec;8(12):1348-58
17115033
Genes Dev. 2008 May 15;22(10):1319-24
18443145
Mol Cell. 2007 Jul 6;27(1):107-19
17612494
Blood. 2009 Jun 11;113(24):6061-8
19289854
Mol Cell Biol. 2003 Jan;23(1):186-94
12482972
Nature. 2000 Nov 23;408(6811):433-9
11100718
Blood. 2004 Mar 1;103(5):1823-8
14615372
Int J Hematol. 2008 Jan;87(1):3-9
18224407
Leukemia. 2009 Aug;23(8):1490-9
19262598
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54
15640349
Science. 2002 Jul 26;297(5581):552-7
12142524
Mol Cell Biol. 2000 Nov;20(22):8602-12
11046155
Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804
15459660
Nature. 2000 Apr 6;404(6778):613-7
10766245
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1093-8
19144918
Genes Dev. 2007 Mar 1;21(5):497-518
17344412